A spiro compound represented by the following formula (I) 1 wherein R.sup.1 and R.sup.2 are the same or different and each is a hydrogen atom, a chlorine atom and the like, n is 1, 2 or 3, a bond containing a broken line is a single bond or a double bond, A is --X--(CH.sub.2).sub.q--N(R.sup.3)(R.sup.4); a group represented by the following formula (a) 2 and the like, wherein X is an oxygen atom or a sulfur atom, q is 2 or 3, R.sup.3 and R.sup.4 are the same or different and each is a C.sub.1-6 alkyl group and the like, or R.sup.3 and R.sup.4 optionally form, together with the adjacent nitrogen atom, a piperidine ring and the like optionally substituted by one or two C.sub.1-6 alkyl and the like, R.sup.5 is a C.sub.1-6 alkyl group and the like, R.sup.6 is a hydrogen atom and the like, and r and t are each independently one or two, or a pharmaceutically acceptable acid addition salt thereof. The compound is useful as a selective estrogen receptor modulator having a climacteric syndrome-ameliorating effect, and can be expected to be a drug for the prophylaxis and/or treatment of osteoporosis, climacteric syndrome and breast cancer.